UCSF Expert Says "Ideal" TB Vaccine Is Needed In Order To Halt Global Public Health Problem

August 26, 1998

SAN FRANCISCO--There is a critical need for a new, effective vaccine to fight tuberculosis, which causes more adult deaths worldwide than any other infectious disease, a TB specialist at the University of California San Francisco emphasized here today.

Speaking at the International Symposium on TB Vaccine Development and Evaluation, Philip C. Hopewell, MD, professor of medicine and associate dean for the UCSF School of Medicine at San Francisco General Hospital, outlined the clinical characteristics of the ideal vaccine.

Most important, he said, is a new model that offers protection at three levels: prevents new infection, prevents persons already infected with TB from developing active TB disease, and prevents reinfection in those who previously had been infected. "This would halt the chain that perpetuates widespread infection, and it is the only way to effectively eliminate TB as a global health problem," he added.

At present, the only existing TB vaccine is the bacille Calmette-Guerin (BCG) vaccine, which has prevented deaths in children but has not proved protective in adults. BCG has been in use for the past 70 years primarily in developing countries, but it has had little impact on the spread of TB, he said.

Recognized nationally in the field of TB control and prevention, Hopewell said the worldwide goal of disease elimination in the next few years is finally realistic because the U.S. public health community is now coming together for the first time with total support for new TB vaccine development.

"This meeting is part of the commitment and it includes all the right experts--from national and international groups--to make it happen," he said. "In addition, scientific advances in understanding the genetic and molecular structure of the TB bacteria make creation of the ideal vaccine more doable." "A basic premise of a new vaccine is that it should be feasible in all areas of the world," Hopewell said.

Other ideal characteristics are:Caused by the organism Mycobacterium tuberculosis, TB is a chronic bacterial infection that usually affects the lungs but also attacks other organs. It is spread through the air when a person with active TB disease of the lungs or larynx coughs, sneezes, or shouts. It is most prevalent in densely populated areas and the inner-city where people often live in close quarters.

Worldwide, an estimated 2 billion persons--one-third of the world population--are infected with TB, and about 3 million die each year from the disease. Areas with the highest rates of infection include Sub-Saharan Africa, India, China, and the Philippines.

An estimated 15 million Americans are infected, although only about 10 percent of those infected ever develop the disease. An estimated 10-12 percent of the San Francisco population is infected.

Factors contributing to TB infection rates in the U.S. include the HIV/AIDS epidemic, because persons with HIV are particularly vulnerable to infection; increased numbers of immigrants from countries with a high incidence of TB and crowded housing; and an increased population of homeless and injection drug users.

Over the past decade, spread of the disease in the U.S. has been effectively controlled through public health programs that focus on early diagnosis and treatment and on follow-up with contacts of infectious patients. Still, the rate of TB in the U.S. is nearly 75 times higher than the level necessary to completely eliminate the disease nationally, according to Hopewell With early diagnosis, TB can be successfully treated with a 6-month regimen of medication, but strict compliance is necessary or drug-resistance can develop.

"While our public health strategy may be considered an effective control measure, it also is inefficient because it relies on the identification of symptomatic patients who may already have spread infection," Hopewell said.

In developing nations, screening programs and treatment follow-up are difficult to maintain because of limited resources, which underscores the critical need for a vaccine, he added.

The three-day symposium in San Francisco is co-sponsored by the National Institute of Allergy and Infectious Disease, American Lung Association of Metropolitan Chicago, International Union Against Tuberculosis and Lung Disease, Centers for Disease Control and Prevention, and World Health Organization.
-end-
Note To The Media:

Reporters who would like to interview Dr. Hopewell can reach him through his UCSF/SFGH office at (415) 206-8509.

The International Symposium on TB Vaccine Development and Evaluation is taking place August 26-28 at the Parc Fifty-Five Hotel in San Francisco (415) 392-8000.
-end-


University of California - San Francisco

Related Tuberculosis Articles from Brightsurf:

Scientists find new way to kill tuberculosis
Scientists have discovered a new way of killing the bacteria that cause tuberculosis (TB), using a toxin produced by the germ itself.

Blocking the iron transport could stop tuberculosis
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply.

Tuberculosis: New insights into the pathogen
Researchers at the University of W├╝rzburg and the Spanish Cancer Research Centre have gained new insights into the pathogen that causes tuberculosis.

Unmasking the hidden burden of tuberculosis in Mozambique
The real burden of tuberculosis is probably higher than estimated, according to a study on samples from autopsies performed in a Mozambican hospital.

HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.

Reducing the burden of tuberculosis treatment
A research team led by MIT has developed a device that can lodge in the stomach and deliver antibiotics to treat tuberculosis, which they hope will make it easier to cure more patients and reduce health care costs.

Tuberculosis: Commandeering a bacterial 'suicide' mechanism
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein.

A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.

How damaging immune cells develop during tuberculosis
Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.

How many people die from tuberculosis every year?
The estimates for global tuberculosis deaths by the World Health Organisation (WHO) and the Institute for Health Metrics and Evaluation (IHME) differ considerably for a dozen countries, according to a study led by ISGlobal.

Read More: Tuberculosis News and Tuberculosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.